KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (2016 - 2025)

Jazz Pharmaceuticals has reported Shares Outstanding over the past 14 years, most recently at $61.4 million for Q4 2025.

  • Quarterly Shares Outstanding rose 1.33% to $61.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.4 million through Dec 2025, up 1.33% year-over-year, with the annual reading at $61.4 million for FY2025, 1.33% up from the prior year.
  • Shares Outstanding was $61.4 million for Q4 2025 at Jazz Pharmaceuticals, up from $60.7 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $63.4 million in Q2 2023 and troughed at $4.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $61.1 million (2021), against an average of $44.2 million.
  • Biggest five-year swings in Shares Outstanding: plummeted 93.67% in 2023 and later soared 1475.7% in 2024.
  • Tracing JAZZ's Shares Outstanding over 5 years: stood at $61.6 million in 2021, then grew by 2.57% to $63.2 million in 2022, then plummeted by 93.67% to $4.0 million in 2023, then soared by 1415.78% to $60.6 million in 2024, then grew by 1.33% to $61.4 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $61.4 million, $60.7 million, and $60.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.